Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 11,164,000 | 11,459,000 | 11,369,000 | 11,142,000 | 10,358,000 |
| Cost of Goods | 4,890,000 | 4,922,000 | 5,075,000 | 4,854,000 | 4,468,000 |
| Gross Profit | 6,274,000 | 6,537,000 | 6,294,000 | 6,288,000 | 5,890,000 |
| Operating Expenses | 4,929,000 | 4,286,000 | 4,237,000 | 4,236,000 | 4,197,000 |
| Operating Income | 1,345,000 | 2,251,000 | 2,057,000 | 2,052,000 | 1,693,000 |
| Interest Expense | 174,000 | 120,000 | 121,000 | 121,000 | 131,000 |
| Other Income | 278,000 | 227,000 | 244,000 | 219,000 | 216,000 |
| Pre-tax Income | 1,449,000 | 2,358,000 | 2,180,000 | 2,150,000 | 1,778,000 |
| Income Tax | 372,000 | 582,000 | 536,000 | 371,000 | 453,000 |
| Net Income Continuous | 1,077,000 | 1,776,000 | 1,644,000 | 1,779,000 | 1,325,000 |
| Net Income | $1,077,000 | $1,776,000 | $1,644,000 | $1,779,000 | $1,325,000 |
| EPS Basic Total Ops | 0.62 | 1.01 | 0.94 | 1.02 | 0.76 |
| EPS Basic Continuous Ops | 0.62 | 1.02 | 0.94 | 1.02 | 0.76 |
| EPS Diluted Total Ops | 0.61 | 1.01 | 0.94 | 1.01 | 0.76 |
| EPS Diluted Continuous Ops | 0.62 | 1.02 | 0.94 | 1.02 | 0.76 |
| EPS Diluted Before Non-Recurring Items | 1.15 | 1.50 | 1.30 | 1.26 | 1.09 |
| EBITDA(a) | $2,148,000 | $3,043,000 | $2,848,000 | $2,829,000 | $2,449,000 |